

NEUROCRINE BIOSCIENCES INC

Form 8-K

December 22, 2006

**Table of Contents**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of the earliest event reported): December 21, 2006**

**NEUROCRINE BIOSCIENCES, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other  
jurisdiction of  
incorporation or  
organization)

**0-22705**

(Commission File  
Number)

**33-0525145**

(IRS Employer Identification  
No.)

**12790 El Camino Real**

(Address of principal executive  
offices)

**92130**

(Zip Code)

Registrant's telephone number, including area code: **(858) 617-7600**

**N/A**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
-

**TABLE OF CONTENTS**

ITEM 5.02 OTHER EVENTS

ITEM 9.01. EXHIBITS

SIGNATURES

EXHIBIT INDEX

EXHIBIT 10.1

EXHIBIT 99.1

---

**Table of Contents**

**ITEM 5.02 OTHER EVENTS.**

On December 21, 2006, the Company announced that Wendell Wierenga, Ph.D, Executive Vice President of Research and Development has resigned from the Company. Dr. Wierenga will remain as a consultant to the Company through 2008. The Company will pay Dr. Wierenga \$25,000 per year, which is payable in four bi-annual installments of \$12,500 beginning on June 1, 2007 and ending on December 31, 2008 for a maximum retainer of \$50,000. The Company also announced that Christopher O'Brien, M.D., Senior Vice President of Clinical Development, has been appointed Chief Medical Officer, Haig Bozigian, Ph.D has been promoted to Senior Vice President of Pharmaceutical and Preclinical Development and Dimitri E. Grigoriadis, Ph.D has been promoted to Vice President of Research.

**ITEM 9.01. EXHIBITS**

10.1 Consulting agreement between Neurocrine Biosciences, Inc. and Wendell Wierenga Ph.D.

99.1 Press release dated December 21, 2006.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: December 21, 2006

NEUROCRINE BIOSCIENCES, INC.

/s/ Timothy P. Coughlin

Timothy P. Coughlin

Vice President and Chief Financial Officer

---

**Table of Contents**

**EXHIBIT INDEX**

Exhibit Number	Document Description
10.1	Consulting agreement between Neurocrine Biosciences, Inc. and Wendell Wierenga, Ph.D.
99.1	Press release dated December 21, 2006